NCT05505292

Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: State University of New York College of Optometry · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, single site, randomized, double masked, comparator-controlled study designed to evaluate the efficacy of lifitegrast ophthalmic solution 5% in treating the symptoms of dry eye in soft contact lens wearers as compared to control. We hypothesize that there will be a significant improvement in dry eye symptoms in contact lens wearers using lifitegrast as compared to those being treated with control (lifitegrast vehicle).

Conditions

• Dry Eye

Interventions

Type	Name	Description
DRUG	Lifitegrast 5% Ophthalmic Solution	Dosed twice a day for 8 weeks
OTHER	Lifitegrast Ophthalmic Solution Vehicle	Dosed twice a day for 8 weeks

Timeline

• Start date: 2022-09-22
• Primary completion: 2023-05-15
• Completion: 2023-05-15
• First posted: 2022-08-17
• Last updated: 2025-01-14
• Results posted: 2025-01-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study